FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	HLIN TI		(Middle)		3. Da	2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE] 3. Date of Earliest Transaction (Month/Day/Year) 06/06/2023							(Ch	eck all appli X Directo	cable) or (give title	Person(s) to Is: 10% Ov Other (s below)	vner	
C/O FATE THERAPEUTICS, INC.; 12278 SCRIPPS SUMMIT DRIVE				4. If /	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	X Form filed by One Reporting Person						
(Street) SAN DII	EGO C.	A	92131		Du	Dula 10hF 1(a) Transaction Indication							Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)		$ _{\Box}$	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date			Code (Instr. 5)				Benefici	es Form ally (D) o Following (I) (In	orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	V Amount		(A) or (D) Price		Transac (Instr. 3			,		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			ansaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
					Code	v	(A)	(D)	Date Exercisable	Exp Dat	oiration te	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$5.52	06/06/2023			A ⁽¹⁾		40,000		(2)	06/0	06/2033	Common Stock	40,000	\$0.00	40,000	D		

Explanation of Responses:

- 1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
- 2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Remarks:

/s/ Cindy Tahl, as Attorney-in-06/07/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.